topiramate and Motion-Sickness

Mal de debarquement syndrome (MdDS) is a balance disorder that typically starts after an extended exposure to passive motion, such as a boat or plane ride. Management is typically supportive (e.g. physical therapy), and symptoms that persist beyond 6 months have been described as unlikely to remit. This study was conducted to evaluate the response of patients with MdDS to management with migraine prophylaxis, including lifestyle changes and medical therapy.. Prospective review.. Ambulatory setting at a tertiary care medical center.. Clinical history, detailed questionnaires, and audiograms were used to diagnose patients with MdDS. Those patients with the diagnosis of the MdDS were placed on our institutional vestibular migraine management protocol. Treatment response was assessed with a quality-of-life (QOL) survey and visual analog scale.. Fifteen patients were diagnosed with MdDS, with a predominance of females (73%) and a mean age of 50 ± 13 years. Eleven patients (73%) responded well to management with a vestibular migraine protocol, which included lifestyle changes, as well as pharmacotherapy with verapamil, nortriptyline, topiramate, or a combination thereof. In comparison, a retrospective control group of 17 patients demonstrated a lower rate of improvement when treated with vestibular rehabilitation and physical therapy.. Management of MdDS as vestibular migraine can improve patients' symptoms and increase the QOL. Nearly all the patients suffering from MdDS had a personal or family history of migraine headaches or had signs or symptoms suggestive of atypical migraine.. 4 Laryngoscope, 127:1670-1675, 2017.

Topics: Adult; Aged; Drug Therapy, Combination; Female; Fructose; Genetic Predisposition to Disease; Humans; Male; Meniere Disease; Middle Aged; Migraine Disorders; Motion Sickness; Nortriptyline; Prospective Studies; Quality of Life; Topiramate; Travel; Travel-Related Illness; Verapamil; Visual Analog Scale

Topics: Adult; Female; Fructose; Humans; Middle Aged; Migraine Disorders; Motion Sickness; Neuroprotective Agents; Topiramate